Artivion, Inc. (AORT)

Market Cap	510.27M
Revenue (ttm)	313.79M
Net Income (ttm)	-19.19M
Shares Out	42.10M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	357.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,063
Open	12.30
Previous Close	12.03
Day's Range	11.96 - 12.49
52-Week Range	9.64 - 23.43
Beta	1.39
Analysts	Buy
Price Target	23.03 (+90.02%)
Earnings Date	May 4, 2023

About AORT

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 1993
• Employees: 1,300
• Stock Exchange: NYSE
• Ticker Symbol: AORT

Financial Performance

In 2022, Artivion's revenue was $313.79 million, an increase of 5.00% compared to the previous year's $298.84 million. Losses were -$19.19 million, 29.4% more than in 2021.

Analyst Forecast

According to 12 analysts, the average rating for AORT stock is "Buy." The 12-month stock price forecast is $23.03, which is an increase of 90.02% from the latest price.

Price Target

$23.03

(90.02% upside)

Analyst Consensus: Buy